title: Development and validation of two liquid chromatography-tandem mass spectrometry methods for the determination of silibinin and silibinin hemisuccinate in human plasma.
abstract: To investigate the pharmacokinetics of silibinin and silibinin hemisuccinate in human plasma, two high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) methods were developed and validated. The methods require a small volume of sample (100μL), and the recovery of the analytes was complete with a good reproducibility (CV% 1.7-9.5), after a simple protein precipitation. Naringenin was used as internal standard. The chromatographic methods provided a good separation of diastereoisomers A and B of both silibinin and silibinin hemisuccinate onto a Chromolith Performance RP18e 100mm×3mm column, with a resolution of peaks from plasma matrix in less than 6min. The methods precision values expressed as CV% were always ≤6.2% and the accuracy was always well within the acceptable 15% range. Quantification was performed on a triple-quadrupole tandem mass spectrometer by Selected Reaction Monitoring (SRM) mode, in a negative ion mode, via electrospray ionization (ESI). The lower limit of quantitation was set at 5.0ng/mL (silibinin) and 25.0ng/mL (silibinin hemisuccinate), and the linearity was validated up to 1000.0 and 12,500.0ng/mL, for silibinin and silibinin hemisuccinate, respectively, with correlation coefficients (R(2)) of 0.991 or better. The methods were suitable for pharmacokinetic studies and were successfully applied to human plasma samples from subjects treated intravenously with Legalon(®) SIL at the dose of 20mg/kg, expressed as silibinin.
authors: Rottapharm|Madaus, R&D Division, Monza, Italy.
authors: Federica
authors: F
authors: Sala
authors: Eurofins|ADME BIOANALYSES, Vergeze, France.
authors: Pablo
authors: P
authors: Albares
authors: Rottapharm|Madaus, R&D Division, Monza, Italy.
authors: Milena
authors: M
authors: Colovic
authors: Rottapharm|Madaus, R&D Division, Monza, Italy. Electronic address: stefano.persiani@rottapharm.com.
authors: Stefano
authors: S
authors: Persiani
authors: Rottapharm|Madaus, R&D Division, Monza, Italy.
authors: Lucio C
authors: LC
authors: Rovati
mesh_terms: D000975:Antioxidants / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D006801:Humans; D007536:Isomerism; D057230:Limit of Detection; D008297:Male; D020944:Silybum marianum / Q000737:chemistry; D015203:Reproducibility of Results; D000077385:Silybin; D012838:Silymarin / Q000032:analysis / Q000097:blood*; D013386:Succinates / Q000032:analysis / Q000097:blood*; D053719:Tandem Mass Spectrometry / Q000379:methods*
chemical_list: D000975:Antioxidants; D012838:Silymarin; D013386:Succinates; D000077385:Silybin
keywords: ACD; HCV; HPLC–MS/MS; IFN; MF; MP; NMF; Pharmacokinetics; SOC; SRM; Silibinin; Silibinin hemisuccinate; TNF; UHQ; Validation; acid citrate dextrose; hepatitis C virus; interferon; matrix factor; mobile phase; normalized matrix factor; selected reaction monitoring; standard of care; tumor necrosis factor; ultra high quality